Verastem Oncology Key 2024 Strategic Priorities and Upcoming Catalysts

 Expect to Begin Rolling Submission of New Drug Application (NDA) for Accelerated Approval to FDA for Avutometinib and Defactinib Regimen in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024; Prepare for Potential Commercial Launch in 2025

Initial Data Read-Out from RAMP 205 Trial of Avutometinib and Defactinib Combination Plus Standard of Care Chemotherapy in Frontline Metastatic Pancreatic Cancer Planned for H1 2024

Data from RAMP 203 and RAMP 204 Trials in KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Planned for Mid-2024

https://www.biospace.com/article/releases/verastem-oncology-outlines-key-2024-strategic-priorities-and-upcoming-catalysts-for-advancing-avutometinib-and-defactinib-and-broader-pipeline-in-ras-pathway-driven-cancers/